Stockreport
Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth [Yahoo! Finance]
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Gliosarcoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, covering global market size, regional shares, market trends, and strategic opportunities for stakeholders. The gliosarcoma market has experienced notable expansion in recent years, with a projected growth from $1.25 billion in 2025 to $1.32 billion in 2026, at a compound annual growth rate (CAGR) of 5.3%. This growth is underpinned by limited clinical understanding, advances in neuro-pathology, the growth of oncology research institutes, improved imaging technologies, and enhanced academic research interests. Looking ahead, strong growth is anticipated as the market climbs to $1.6 billion by 2030, at a 5% CAGR. Key drivers include increased funding for rare cancer research, precision diagnostics development, refined treatment protocols, molecular testing expansion, and heightened research center collabor
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | NVCR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
NVCR alerts
NVCR alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
NEWS
NEWS
- Novocure to Report First Quarter 2026 Financial Results[Business Wire]
- Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer[Business Wire]
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer[Business Wire]
- NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance][Yahoo! Finance]
- Novocure to Participate in 2026 Leerink Global Healthcare Conference[Business Wire]
- More
NVCR
SEC Filings
SEC Filings
- 3/26/26 - Form SCHEDULE
- 3/26/26 - Form 8-K
- 3/5/26 - Form 4
- NVCR's page on the SEC website
- More